Investigational Drug Information for Pevonedistat
✉ Email this page to a colleague
What is the development status for investigational drug Pevonedistat?
Pevonedistat is an investigational drug.
There have been 34 clinical trials for Pevonedistat.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 13th 2019.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and Takeda.
There are one hundred and fourteen US patents protecting this investigational drug and zero international patents.
Summary for Pevonedistat
| US Patents | 114 |
| International Patents | 2,001 |
| US Patent Applications | 425 |
| WIPO Patent Applications | 278 |
| Japanese Patent Applications | 159 |
| Clinical Trial Progress | Phase 2 (2019-08-13) |
| Vendors | 46 |
Recent Clinical Trials for Pevonedistat
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes | Takeda | Phase 2 |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
| Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | Millennium Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for Pevonedistat
Top disease conditions for Pevonedistat
Top clinical trial sponsors for Pevonedistat
US Patents for Pevonedistat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Pevonedistat | ⤷ Sign Up | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Sign Up |
| Pevonedistat | ⤷ Sign Up | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | ⤷ Sign Up |
| Pevonedistat | ⤷ Sign Up | Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D- ]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate | Millennium Pharmacetuicals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| Pevonedistat | ⤷ Sign Up | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (Cambridge, MA) | ⤷ Sign Up |
| Pevonedistat | ⤷ Sign Up | Method of reducing titers of antibodies specific for a therapeutic agent | Duke University (Durham, NC) | ⤷ Sign Up |
| Pevonedistat | ⤷ Sign Up | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | ⤷ Sign Up |
| Pevonedistat | ⤷ Sign Up | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | AbbVie Inc. (North Chicago, IL) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Pevonedistat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Pevonedistat | European Patent Office | EP3131552 | 2034-04-16 | ⤷ Sign Up |
| Pevonedistat | Spain | ES2823756 | 2034-04-16 | ⤷ Sign Up |
| Pevonedistat | Japan | JP2017514806 | 2034-04-16 | ⤷ Sign Up |
| Pevonedistat | Japan | JP2019070012 | 2034-04-16 | ⤷ Sign Up |
| Pevonedistat | Japan | JP2021059548 | 2034-04-16 | ⤷ Sign Up |
| Pevonedistat | Japan | JP6838085 | 2034-04-16 | ⤷ Sign Up |
| Pevonedistat | New Zealand | NZ629860 | 2034-04-16 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
